1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2 (mIDH2)
    Meeting Abstract

    Fathi, A. T.; Dinardo, C. D.; Kline, I.; Kenvin, L.; Gupta, I.; Attar, E. C.; Stein, E. M.; de Botton, S.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Palliative care from cancer diagnosis for all: Memorial Sloan Kettering's "One-Two-Three" program
    Meeting Abstract

    Epstein, A. S.; Klimek, V. M.; Chow, K.; Desai, A. V.; Wan, P. J.; Anderson, K.; Ranghan, C.; Okpako, M.; Rawlins-Duell, R.; Kramer, D.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Venetoclax (VEN) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL)
    Meeting Abstract

    Davids, M. S.; Roberts, A. W.; Seymour, J. F.; Wierda, W. G.; Puvvada, S. D.; Gressick, L. A.; Alter, D.; Zhou, L.; Kim, S. Y.; Verdugo, M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • First-line (1L) avelumab treatment in patients (pts) with metastatic Merkel cell carcinoma (mMCC): Preliminary data from an ongoing study
    Meeting Abstract

    D'Angelo, S. P.; Russell, J.; Hassel, J. C.; Lebbe, C.; Chmielowski, B.; Rabinowits, G.; Terheyden, P.; Brownell, I.; Zwiener, I.; Bajars, M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A multi-center phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401)
    Meeting Abstract

    D'Angelo, S. P.; Mahoney, M. R.; Van Tine, B. A.; Atkins, J. N.; Milhem, M. M.; Tap, W. D.; Antonescu, C. R.; Horvath, L. E.; Schwartz, G. K.; Streicher, H.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
    Meeting Abstract

    Cook, R. J.; Stein, E.; Steensma, D. P.; Sekeres, M. A.; Bixby, D. L.; Rizzieri, D.; Jurcic, J. G.; Vigil, C. E.; Redner, R.; Roboz, G. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Evidence of low incidence of myelodysplastic syndrome (MDS) in patients exposed to bendamustine treatment for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
    Meeting Abstract

    Burke, J. M.; Bibeau, K.; Kahl, B.; Carson, K. R.; Zelenetz, A. D.; Brander, D. M.; Maddocks, K. J.; Gerecitano, J. F.; Pathak, A. K.; Cheson, B. D.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Correlation of circulating PD-L2 levels with outcomes of therapy with the anti-PD-1 antibody pembrolizumab (P) in patients (pts) with advanced soft tissue sarcomas (STS): Biomarker analysis of SARC028
    Meeting Abstract

    Burgess, M. A.; Roszik, J.; Van Tine, B. A.; Hu, J.; Schuetze, S.; D'Angelo, S. P.; Attia, S.; Priebat, D. A.; Okuno, S. H.; Riedel, R. F.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses
    Meeting Abstract

    Burgess, M. A.; Bolejack, V.; Van Tine, B. A.; Schuetze, S.; Hu, J.; D'Angelo, S. P.; Attia, S.; Priebat, D. A.; Okuno, S. H.; Riedel, R. F.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase I dose escalation of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL)
    Meeting Abstract

    Batlevi, C. L.; Hamlin, P. A.; Matasar, M. J.; Horwitz, S. M.; Gerecitano, J. F.; Moskowitz, C. H.; Straus, D. J.; Zelenetz, A. D.; Drullinsky, P.; Copeland, A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save